About Us
Verve Therapeutics was created with a singular focus: to protect the world from heart disease
Our Mission
Verve is focused on discovering and developing medicines that safely edit the adult genome and mimic naturally protective gene variants to treat coronary heart disease, the leading cause of death worldwide.
Verve brings together two of the biggest breakthroughs in 21st century biomedicine — human genetic analysis and gene editing — to realize a new future, one of longevity and vitality for tens of millions of people around the globe with or at risk for cardiovascular disease.
Verve Team
Verve has been purpose-built for the task ahead, with a founding team of world-leading experts in cardiovascular medicine, human genetics, gene editing delivery technology and safety, and drug development.
Burt Adelman, M.D.
Co-Founder and Chairman of the Board
Michael Amaonye
Research Associate
Andrew Ashe, J.D.
President and Chief Operating Officer
Aaron Beach
Principal Scientist, Analytical Chemistry
Maggie Beaudoin
Vice President, Finance
Andrew Bellinger, M.D., Ph.D.
Chief Scientific Officer
Souvik Biswas, Ph.D.
Principal Scientist, Formulation & Chemistry
Maurine Braun
Senior Manager, Preclinical Operations and Toxicology
Alexandra Chadwick, Ph.D.
Associate Director, Preclinical Research and Development
Huei-Mei Chen, Ph.D.
Senior Scientist, Gene Editing
Christopher J. Cheng, Ph.D.
Senior Director, RNA Technology and Manufacturing
Victoria Clendaniel
Senior Research Associate
Angela Cook
Chief of Staff
Ishwin Dembla, M.S.
Senior Scientist, Analytical Chemistry
Jamie DeNizio, Ph.D.
Senior Scientist
Joseph DePeter
Senior Process Development Engineer, mRNA Process Development and Tech Transfer
Chaitali Dutta, Ph.D.
Principal Scientist, Pharmacology and Toxicology
Robin Eisner
Administrative and Operations Manager
Yasser (Yas) El-Gamal
Vice President, Legal Affairs and Chief Intellectual Property Counsel
Richard Falzone
Vice President, Clinical Operations
Nancy Fuselli, BSc, RAC
Senior Director, Quality Affairs
Jack Ganey
Associate Scientist
Soumya Gangopadhyay, Ph.D.
Senior Scientist, Bioassays and Editing
Sara Garcia, Ph.D.
Senior Scientist, Computational Biology
Ryan Garrity
Senior In Vivo/In Vitro Research Associate
Kevin Gichuru
Accounting Manager
Zachary Glass, Ph.D.
Scientist, Formulation
Matthew Greenfield
Associate Director, Laboratory Operations
Sowmya Iyer, Ph.D.
Senior Scientist, Computational Biology
J. Keith Joung, M.D., Ph.D.
Co-Founder
Lisa Kasiewicz, Ph.D.
Senior Scientist, Formulations
Sekar Kathiresan, M.D.
Co-Founder, Chief Executive Officer and Board Member
Jaime Kirk
Senior Manager, Technical Accounting
Jeong-Ah Kwon
Scientist, RNA Analytics
Jennifer Lavoie
Associate Director, CMC Program Management
Jimmy Li
Staff Accountant
James Madsen, Ph.D.
Associate Director, Mass Spectrometry
Padma Malyala
Executive Director, Formulation and Characterization
Yuri Matsumoto, Ph.D.
Principal Scientist, Bioanalytical and Translational Sciences
Anne Marie Mazzola
Study Coordinator and Scientist, Pharmacology and Toxicology
Harlisa Minaya
Senior Human Resources Generalist
Taiji Mizoguchi, Ph.D.
Senior Scientist, In Vivo Biology
Kiran Musunuru, M.D., Ph.D., MPH
Co-Founder and Senior Scientific Advisor
Ash Nagpal
Senior Process Engineer
Robyn Naigles
Administrative and Operations Associate
Yusuf Nasrullah
Scientist
Joan Nickerson
Senior Vice President, Human Resources
April O'Neil
Associate Director, Human Resources
Anthony Philippakis, M.D., Ph.D.
Co-Founder and Board Member
Colin Platt, Ph.D.
Scientist, In Vivo Pharmacology
Jason Politi
Senior Vice President, Technical Operations
Brent V. Powell, Ph.D.
Scientist
Kallanthottathil G. Rajeev, Ph.D.
Vice President, CMC
Caroline Reiss, Ph.D.
Senior Scientist, RNA Technology and Manufacturing
Huilan Ren
Associate Scientist
Ellen Rohde, Ph.D.
Vice President, Pharmacology and Toxicology
Issi Rozen, MBA
Co-Founder and Strategic Advisor
Athul Sanjeev
Research Associate
Wynn Shatzer
Research Associate
Maddy Shay
Research Associate, Formulation and Characterization
Mary Stahley, Ph.D.
Associate Director, Process Development and Technical Operations
Leslie Stolz, Ph.D.
Vice President, Regulatory Affairs
Lynnsey Street
Associate Scientist
Barry Ticho, M.D., Ph.D.
Co-Founder
Scott Vafai, M.D.
Executive Director, Translational Medicine
Kui Wang, Ph.D.
Senior Scientist
Min (Rachel) Zhang
Senior Accountant
Board of Directors
Burt Adelman, M.D.
Co-Founder and Chairman of the Board
Jessica Alston, Ph.D.
Board Observer
Eli Casdin, MBA
Board Observer
John Evans, MBA
Board Member
Sekar Kathiresan, M.D.
Co-Founder, Chief Executive Officer and Board Member
Boris Nikolic, M.D.
Board Observer
Anthony Philippakis, M.D., Ph.D.
Co-Founder and Board Member
Krishna Yeshwant, M.D., MBA
Board Member
Scientific Advisory Board
Eugene Braunwald, M.D.
Andrew Geall, Ph.D.
Penny M. Heaton, M.D.
Daniel J. Rader, M.D.
Collaborations and Licensing
Verve has assembled a portfolio of gene editing and delivery technologies through strategic collaborations and licensing agreements with industry leaders, including Beam Therapeutics, the Broad Institute and Harvard University.
Investors
Verve is supported by a top-tier syndicate of investors who share our vision for tackling the world’s most urgent health challenge.
